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Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates 
are poor due to two predominate reasons. First, the majority of patients present with 
advanced disease creating significant difficulty with effecting disease eradication. 
Second, acquisition of chemotherapy resistance results in untreatable progressive 
disease. Advances in treatment of advanced ovarian cancer involve a spectrum of 
interventions including improvements in frontline debulking surgery and combination 
chemotherapy. Anti-angiogenic factors have been shown to have activity in frontline 
and recurrent disease while novel chemotherapeutic agents and targeted treatments 
are in development particularly for disease that is resistant to platinum-based 
chemotherapy. These developments aim to improve the progression-free and overall 
survival of women with advanced ovarian cancer
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Ovarian cancer is the third most common 
gynecological malignancy worldwide but it 
is the most lethal, responsible for 160,000 
deaths per year [1]. Following surgical deb-
ulking, response rates to initial chemotherapy 
are high with up to 75% of patients having a 
complete clinical response [2]. However, the 
majority of patients will still go on to relapse. 
Once relapse has occurred treatment is not 
curative and unfortunately cure rates have 
changed little in the last 20 years. Ovarian 
cancer frequently responds to multiple lines 
of chemotherapy and new discoveries have 
increased the progression-free survival (PFS) 
and overall survival (OS) [3]. In this review, 
we discuss the recent discoveries and changes 
in the management of advanced ovarian can-
cer that have improved survival and we shed 
light on novel treatments and current areas 
of research.
Advances in surgery
Primary – maximal effort – cytoreductive 
surgery followed by chemotherapy is the 
mainstay of initial treatment for advanced 
ovarian cancer; Féderation Internationale 
de Gynécologie et d’Obstétrique (FIGO) 
stage IC-IV. Research in the 20th century in 
Europe and USA demonstrated that removal 
of as much visible (macroscopic) tumor as 
is technically possible prior to systemic che-
motherapy was the most important factor 
in improving patient outcomes [4]. Initially, 
optimal debulking was defined as residual 
disease of less than 2 cm in the lesion of 
greatest diameter. More recently it has been 
shown that those patients who have no mac-
roscopic disease at the end of surgery have 
greatly improved survival compared with 
those who were debulked with residual dis-
ease [5]. Data analysis has shown that patients 
who have no visible postoperative residual 
disease have a 5-year survival of 63%, but 
in those where the largest residual lesion is 
1–10 mm this falls to 28.6%; demonstrat-
ing the poor prognosis for any residual dis-
ease however small [6]. Therefore complete 
macroscopic debulking surgery has become 
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Figure 1. Overall survival at 1–5 years is dependent 
upon the size of largest residual tumor deposit 
following debulking surgery.  
Data taken with permission from [6].
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the target for primary surgery. Five-year survival falls 
further to 21.3% when residual disease is greater than 
10 mm indicating that upfront surgery cytoreduction 
is of value even if total macroscopic tumor clearance is 
not feasible. This reduction in survival with increasing 
residual disease is demonstrated in Figure 1. The ben-
efit of optimal surgical debulking within the peritoneal 
cavity is present even in patients with FIGO stage IV 
disease [7]. However, the reason for being classed as 
stage FIGO IV disease is important; stage IV due to 
positive pleura cytology alone (now stage IVA) is asso-
ciated with a much higher OS than that due to intra-
parenchymal hepatic metastases (now stage IVB) and 
this finding is reflected in the 2014 update in FIGO 
staging [8].
As surgery is operator dependent, improving surgi-
cal skill and technique may improve outcomes if all 
patients are operated on with the aim of achieving no 
macroscopic residual disease. A large metanalysis of 
3126 patients [6] showed that postoperative residual 
disease overrides the FIGO stage in terms of predict-
ing prognosis, with advanced stage optimally debulked 
patients showing higher survival rates than subop-
timally debulked patients of a lower stage. However, 
there is a subset of patients in whom complete mac-
roscopic debulking is not technically possible due to 
distribution of disease and therefore these patients have 
poorer outcomes. It is not clear whether these patients 
are disadvantaged because their disease is unresectable 
and therefore improvement in surgical technique may 
improve their outlook or whether such patients have 
disease in which inability to carry out resection is a 
surrogate marker of unfavorable disease biology.
A review of the data of SCOTROC by Craw-
ford et al. [7] shed light on this issue of favorable versus 
unfavorable disease. It first showed that patients in 
the UK generally had a lower proportion of patients 
that were optimally debulked compared with similar 
patients in Australia and the USA, which is an ongo-
ing area of controversy. It also showed that optimal 
debulking was associated with improved PFS mainly 
in patients with less extensive disease at diagnosis, 
rather than across all patients as might be expected 
if degree of debulking is a universally critical issue 
in ovarian cancer. This suggests that more extensive 
disease may represent a more aggressive subtype of 
disease and that the poor outcomes from incomplete 
debulking in these patients may be due to differences 
in tumor biology rather than lack of technical skill. 
This may also suggest why complete removal is asso-
ciated with better PFS; because it is a less aggressive 
subtype of disease. Definitive evidence for this theory 
is still sought.
Neoadjuvant chemotherapy
Although primary cytoreductive surgery is considered 
the standard of care in many centers there has been 
considerable interest in the use of neoadjuvant chemo-
therapy followed by interval debulking surgery, due to 
the morbidity associated with maximal effort cytore-
ductive surgery. In their 2010 paper, Vergote et al. [9] 
presented a randomized trial in which patients with 
stage IIIC and IV ovarian cancer were randomized to 
primary cytoreductive surgery or neoadjuvant chemo-
therapy followed by interval debulking. The results 
showed no difference in survival between the two 
groups suggesting that neoadjuvant chemotherapy 
followed by interval debulking was not inferior. Since 
primary cytoreductive surgery carries greater morbid-
ity and mortality risk due to the extent of surgery, it 
may be interpreted that neoadjuvant chemotherapy 
is preferable. However, in this trial surgical quality 
was strongly inhomogeneous with total macroscopic 
tumor clearance rates ranging from 3.9 to 63%. In 
addition OS was just 29 months in the upfront sur-
gery group, compared with 49 months in a compa-
rable group in the GOG172 [10] study carried out in 
the USA. These differences in survival are believed by 
many practitioners to be primarily due to a lower rate 
of low-volume debulking in the Vergote et al. study 
which contributed to the view held by the majority 
of US practitioners that primary debulking surgery 
is still the best practice for most women with ovar-
ian cancer. This leaves unanswered the question of 
adequate timing of surgery with standardized total 
macroscopic debulking. The differences between US 
and European philosophies mean that neoadjuvant 
chemotherapy remains controversial and surgical 
management of ovarian cancer is typically much less 
aggressive in Europe than in the USA.
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In Vergote et al. 80.6% of the neoadjuvant group of 
patients were resected to less than 1 cm with no con-
current increase in OS, as compared with expectations 
from upfront surgery. This suggests that the survival 
advantage of being optimally debulked is lost if neo-
adjuvant chemotherapy has been given and therefore 
that the definition of postoperative residual disease 
after chemotherapy is not the same as the definition 
of residual disease in chemo-naive patients. This poses 
the question of oncologic safety and validity of surgery 
at a delayed time point and the need to redefine the 
meaning of optimal surgery in the neoadjuvant setting.
This view is supported by the Gynecologic Oncology 
Group (GOG) 152 trial in which patients with advanced 
ovarian cancer and residual tumor exceeding 1 cm after 
primary surgery despite maximal surgical effort in the 
hands of experienced surgeons, were randomized after 
three cycles of adjuvant chemotherapy to interval cyto-
reductive surgery plus three further cycles of chemother-
apy or to chemotherapy alone [11]. In this study patients 
had higher optimal debulking rates after three cycles of 
chemotherapy compared with their initial surgery, but 
there was no survival advantage of reoperation after sub-
optimal initial debulking. This study emphasizes the 
point that the impact of tumor residual disease depends 
on the timing of the cytoreductive procedure. In order 
to address the issue of survival benefit of upfront deb-
ulking counterbalanced with higher surgical morbidity, 
a further trial is currently being developed with strictly 
defined qualification criteria for the participating centers 
to ensure surgical quality. This will answer the ques-
tion of the optimal timing of chemotherapy. The study 
is planned as a collaboration between the GOG, AGO, 
GINECO, NOGGO, MITO and MANGO organiza-
tions and is expected to include more than 700 primary 
patients with advanced stage III and IV disease
Secondary debulking surgery
Despite the strong evidence for primary cytoreduc-
tive surgery in ovarian cancer, the evidence for sur-
gery after disease relapse is less well defined. Surgery 
at relapse has two aims; cytoreduction or palliation of 
otherwise untreatable symptoms. Even in cases where 
cytoreduction is the aim, surgery is not curative.
In many centers relapses are surgically excised 
based on local practice before further chemotherapy is 
administered in the belief that this improves survival. 
Retrospective analysis of the DESKTOP dataset of 
patients who have undergone selective secondary deb-
ulking surgery has shown significant improvement in 
survival if recurrent disease was completely resected; 
median survival in complete resection 45.2 versus 
19.7 months if incomplete (hazard ratio [HR]: 3.71; 
95% CI: 2.27–6.05; p < 0.001) [12]. A study prospec-
tively randomizing resectable patients to secondary deb-
ulking surgery or chemotherapy, DESKTOP III [13], 
has been designed to directly compare these strategies. 
In this trial patients with presumed resectable disease 
are randomized between second-line chemotherapy or 
secondary debulking followed by chemotherapy. This 
trial, together with the equivalent American trial GOG 
213 [14] will define the prospective value of surgical 
cytoreduction in platinum-sensitive relapse.
Of note, in all retrospective series so far, cytoreduc-
tive surgery at relapse has been shown to be associated 
with prolongation of OS and PFS only if a total macro-
scopic tumor clearance could be obtained. However, it 
is difficult to predict this preoperatively. Based on the 
DESKTOP dataset the German Arbeitsgemeinschaft 
Gynäkologische Onkologie (AGO) defined a clinical 
‘AGO score’ which could predict total macroscopic 
tumor clearance in more than two of three patients if 
all of the following factors were met; ascites less than 
500 ml, tumor-free surgery at initial presentation of 
disease and good performance status at relapse. The 
number and localization of the relapsed lesions were of 
no significant value if total macroscopic tumor clear-
ance could be obtained. Interestingly, in the DESK-
TOP series the patients with disseminated peritoneal 
carcinomatosis at relapse had the same survival as 
those without peritoneal carcinomatosis if they had no 
macroscopic disease postoperatively [15].
There is also evidence that the value of cytoreductive 
surgery holds beyond first disease recurrence, such that 
wherever complete surgical resection of disease is pos-
sible and the disease is responsive to platinum chemo-
therapy it may be recommended, since surgical effort 
appears to be associated with significantly prolonged 
OS and PFS [16].
Intraoperative mapping
Given the importance of complete macroscopic cyto-
reductive therapy for prolonged survival in ovarian 
cancer, advances that can improve the visualization 
of miniscule tumor deposits during surgery would 
be beneficial. Ovarian cancer cells are known to over 
express folate receptors and intra-operative visualiza-
tion of cancer cells by the development of a folate 
receptor-α-targeted fluorescent agent has shown exper-
imental potential in these patients. By helping to guide 
surgeons in their debulking efforts these experiments 
aim to increase the degree of tumor clearance and 
therefore survival [17]. Other agents such as integrin 
fluorescent imaging are in development and may come 
to play an important role in fully resecting advanced 
ovarian cancer [18]. However, all of the agents described 
in this section are in the early stages of research and 
development.
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Adjuvant chemotherapy
Adjuvant chemotherapy results in a long-term cure 
in 10–15% of advanced ovarian cancer patients and 
improves OS in the remainder [3]. For more than 
a decade platinum analog-based adjuvant chemo-
therapy regimens have been the standard of care fol-
lowing primary cytoreductive surgery. Carboplatin 
which has equivalent efficacy and comparatively less 
toxicity compared with cisplatin has become the most 
widely used platinum-based agent [3]. Many differ-
ent platinum containing combinations have been 
investigated and carboplatin plus paclitaxel given on 
a 3 weekly basis has become the consensus frontline 
treatment [19]. Despite this consensus there is evidence 
that the benefit of adding paclitaxel to a carboplatin 
regimen is small and that in patients who are unable 
to tolerate paclitaxel, carboplatin alone is a reasonable 
first-line option [20]. The most important dose limiting 
toxicity of paclitaxel is neuropathy, the risk of which 
can be reduced with the substitution of docetaxel but 
at the cost of increased myelosuppression [21].
Dose dense regimes
A study by Katsumata et al. [22] in Japan has sug-
gested that dose dense paclitaxel may provide a sig-
nificant survival advantage over standard treatment. 
In this trial women were randomized to a conven-
tional regimen of 3 weekly carboplatin and pacli-
taxel or a dose dense regimen of weekly paclitaxel 
plus 3 weekly carboplatin. Median OS was higher in 
the dose dense regimen group (100.5 months) than 
in the conventional treatment group (62.2 months; 
HR: 0.79; CI: 0.63–0.99; p = 0.039) [23].To confirm 
these findings in a wider ethnic group the Interna-
tional Collaboration on Ovarian Neoplasm (ICON)8 
study [24] is currently trialing conventional 3 weekly 
carboplatin and paclitaxel, to dose dense paclitaxel, 
with conventional and dose dense carboplatin. Two 
trials have already published further data on dose-
dense paclitaxel. The completed Multicenter Italian 
Trials in Ovarian Cancer (MITO-7) study showed 
no difference between its trial arms of three weekly 
carboplatin (AUC 6) plus paclitaxel (175 mg/m2) 
versus weekly carboplatin (AUC 2) plus paclitaxel 
(60 mg/m2) [25]. However, the lower total dose of 
weekly paclitaxel used in this study may have been 
responsible for the negative study findings. GOG262 
has published preliminary results [26]. This study 
compared dose-dense weekly paclitaxel (80 mg/m2) 
and carboplatin (AUC 6) with a conventional three 
weekly carboplatin and paclitaxel. Preliminary results 
show no difference between the two arms. However, 
crucially both arms provided the option of additional 
bevacizumab. This addition makes results difficult to 
interpret as it appears that bevacizumab may reduce 
the advantage of dose dense paclitaxel.
Angiogenesis inhibitors
Despite the improvement in chemotherapy regimens 
the overall improvement in PFS since the discovery of 
the platinum agents has been disappointing. There-
fore, recent research has been focused on understand-
ing the biology of ovarian cancer in order to discover 
new methods of targeting the disease.
Angiogenesis is a complex process regulated by a 
number of endogenous pro- and anti-angiogenic fac-
tors and plays a key role in the growth and metastases 
of solid tumors including ovarian cancer. VEGF is a 
key mediator of angiogenesis and expression of intra-
tumoral VEGF and its receptor are associated with 
poor prognosis in ovarian cancer [27]. Bevacizumab 
is a monoclonal antibody that binds to the isoform 
VEGF-A and has proven efficacy in a range of cancers. 
The ICON7 [28] and the GOG 218 study [29] were two 
landmark trials that defined the role of bevacizumab 
in front-line treatment of advanced ovarian cancer. 
Patients were randomized to three weekly carbo-
platin and paclitaxel with or without bevacizumab. 
Median PFS was improved by 1.5 months in ICON7 
(HR: 0.81; 95% CI: 0.70–0.94; p = 0.004) and 3.8 
months in GOG218 (HR: 0.72; 95% CI: 0.62–0.82; 
p < 0.001) and was restricted to those patients who 
received maintenance bevacizumab for a year or more. 
Although PFS was improved with bevacizumab in 
GOG218 and ICON 7, a benefit in OS has not been 
shown. The PFS advantage then appeared to wane 
once bevacizumab was discontinued and the optimal 
period of time to continue the drug remains unclear. 
Bevacizumab is usually well tolerated but common 
toxicities include hypertension and proteinuria. An 
increase in the frequency of bowel perforation has also 
been observed. Bevacizumab is the first anti-angio-
genesis drug to show an improvement in PFS and on 
the basis of these trials the EMA has approved beva-
cizumab for front line use. In contrast the National 
Institute for Clinical Excellence has not provided 
funding on the basis of lack of cost–effectiveness [30], 
as bevacizumab costs GB£128,000–£161,000 per 
quality-adjusted life year (QALY) gained. The appro-
priate role for bevacizumab in ovarian cancer in the 
up-front adjuvant setting is not yet determined.
A number of VEGF pathway inhibitors have been 
trialed besides bevacizumab. Pazopanib is an oral tyro-
sine kinase inhibitor that inhibits several kinase recep-
tors including VEGF, PDGF and FGF. The PDGF 
and FGF pathways have been shown to be involved 
in angiogenesis and may be involved in the resis-
tance mechanisms to VEGF receptor inhibitors [27]. 
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AGO-OVAR-16 [31] is a large Phase III trial compar-
ing 24 months of maintenance pazopanib vs placebo 
in 940 women with advanced ovarian cancer. Patients 
in the pazopanib arm had a PFS of 17.9 months ver-
sus 12.3 months in the placebo arm (HR: 0.76; 95% 
CI: 0.64–0.91; p = 0.002). The most common tox-
icity was hypertension (31% grade 3/4), with other 
toxicities including diarrhoea, hepatic impairment 
and neutropenia. The result of this trial suggests that 
maintenance pazopanib is a potential oral alternative 
to bevacizumab, although head to head comparison 
trials have not been undertaken. However, as the use 
of VEGF antagonists in the up-front setting remains 
controversial, they have not been incorporated into 
clinical trials as the ‘standard’ arm in the treatment of 
advanced disease.
Alternative angiogenic pathways are also being tar-
geted as potential treatments for ovarian cancer. One 
of these pathways involves angiopoietins; which are 
cytokines involved in the regulation of angiogenesis 
and inflammation. Novel peptibodies which selec-
tively neutralize specific angiopoietins have shown 
promise in Phase II clinical trials in recurrent ovarian 
cancer [27] and in the future may provide new adjuvant 
treatments.
Intraperitoneal chemotherapy
As the development of new targeted therapies for ovar-
ian cancer has been limited, research has also focused 
on delivering existing chemotherapeutic agents in 
novel ways. Since ovarian cancer frequently has an 
intraperitoneal distribution at diagnosis, intraperi-
toneal instillation of chemotherapy has been investi-
gated as a way of exposing tumor tissue to extremely 
high levels of chemotherapy. Studies have shown that 
intraperitoneal concentrations of intraperitoneal cis-
platin may reach 12–21-fold the concentration of the 
plasma [32]. Therefore the intraperitoneal route may be 
expected to have improved disease control in addition 
to reduced systemic adverse effects. The first random-
ized trial of intraperitoneal chemotherapy, published in 
1996 GOG 104 [33], supported both of these aspects. In 
this trial patients were given the same dose of cisplatin 
(100 mg/m2) intraperitoneal or intravenous (iv.) along 
with cyclophosphamide iv. for six cycles. Median sur-
vival in the intraperitoneal arm was significantly longer 
at 49 months compared with 41 months in the iv. arm 
(HR: 0.76; CI: 0.61–0.96; p = 0.02). Grade III/IV 
neutropenia, clinical hearing loss, and neuromuscu-
lar toxic effects were all reduced in the intraperito-
neal group. Two subsequent trials; GOG114 [34] and 
GOG172 [10] confirmed the finding of increased sur-
vival. However, they showed increased grade III/IV 
adverse effects, particularly fatigue, gastrointestinal 
and hematological effects. As a result of these adverse 
effects only 18% and 42% of patients completed the 
assigned intraperitoneal chemotherapy in the respec-
tive trials leading to serious concerns about intraperi-
toneal toxicity. An additional problem of GOG172 and 
GOG114 trials lay in their design. While GOG104 
was a simple substitution of iv. for intraperitoneal che-
motherapy, both of the subsequent trials had unequal 
control and treatment arms (Figure 2) such that it is dif-
ficult to be certain that the positive results of these tri-
als were due to superiority of the intraperitoneal route. 
Consistent evidence of significantly increased survival 
led the National Cancer Institute (NCI) in the USA to 
recommend the use of frontline intraperitoneal chemo-
therapy in 2006 [35]. Improvements in port placement 
and management may significantly reduce toxicities 
and there are a number of centers worldwide that use 
and develop this promising form of therapy. However, 
lack of experience with this route of chemotherapy and 
uncertainty over its risk of complications has meant 
that it has yet to be widely adopted.
Areas for further research include substituting cis-
platin with carboplatin to look for reduced intraperi-
toneal toxicity and a definitive trial with balanced che-
motherapy doses to confirm that intraperitoneal is a 
superior route of administration.
In an exploratory retrospective subanalysis of 
GOG172 by Lesnock et al. the tumors were analyzed 
for expression of the Breast Cancer 1 (BRCA1) pro-
tein [36]. This study showed that patients with tumors 
that had reduced BRCA1 expression had longer OS in 
response to intraperitoneal chemotherapy (84 months) 
than iv. (47 months; HR: 0.67; 0.67 CI: 0.47–0.97; 
p = 0.03). However, the benefit of intraperitoneal vs. iv. 
chemotherapy was lost in tumors with normal BRCA1 
expression. It would therefore appear that the benefit 
of intraperitoneal chemotherapy may be restricted to 
those with reduced BRCA1 expression. Prospective 
trials are needed to confirm this finding and with a 
36 month survival advantage it would appear prudent 
to design trials involving intraperitoneal treatment in 
those with aberrant BRCA1 expression, particularly 
those with inherited BRCA1 mutations.
BRCA1- & BRCA2-related disease
BRCA1 and BRCA2 are dominantly inherited can-
cer susceptibility genes that were first discovered in 
families with high rates of breast cancer. Mutations in 
these genes have been found to be common in women 
with high-grade serous cancer (HGSC), which is the 
most common histological subtype of ovarian can-
cer. BRCA germline mutations are seen in 13–16% of 
HGSC and somatic mutations are detected in another 
6% of cases. The lifetime risk of HGSC is up to 60% 
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Figure 2. Design of GOG114and GOG172.  
ip.: Intraperitoneal; iv..: Intravenous. 
GOG114
Stage III ovarian cancer
debulked to ≤1 cm
GOG172
Stage III ovarian cancer
debulked to ≤1 cm
Arm 1
Cisplatin 75 mg/m2 iv.
Paclitaxel 135mg/m2 iv.
21-day cycle × 6
Carboplatin AUC 9 x 2 iv.*
28 day cycle x 2
Cisplatin 100 mg/m2 ip.**
Paclitaxel 135 mg/m2 iv.
21-day cycle × 6
Paclitaxel 135 mg/m2 iv. day 1 
Cisplatin 75 mg/m2 iv. day 2
21-day cycle × 6
Paclitaxel 135 mg/m2 iv.
Cisplatin 100 mg/m2 ip. day 2†
Paclitaxel 60 mg/m2 ip. day 8‡
21-day cycle × 6
Arm 2
Arm 1
Arm 2
          Control arm
*Additional dose of iv. carboplatin
**Increased dose ip. cisplatin
------ Trial arm
†Increased dose ip. cisplatin
‡Additional dose ip. paclitaxel 
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in BRCA1 mutation carriers, and up to 27% in those 
with BRCA2 [37]. Women who are known carriers are 
offered pre-emptive salipingo-oophrectomy after com-
pletion of their families to substantially reduce their 
risk of developing ovarian cancer.
Patients with HGSC that carry BRCA muta-
tions have been shown to be particularly sensitive to 
platinum-based chemotherapy, and frequently have 
sustained response to repeated treatments with these 
agents [38]. This increased sensitivity to platinum 
agents may explain the prolonged survival in the intra-
peritoneal trials mentioned previously, since BRCA 
patients may have particular sensitivity to the higher 
intratumoral concentrations of platinum agents.
PARP inhibitors
The BRCA genes encode proteins that sense DNA 
damage and are involved in double standed (ds)
DNA repair via homologous recombination. Cell 
lines carrying these mutations are therefore deficient 
in dsDNA repair and rely upon single stranded (ss)
DNA repair mechanisms to resolve DNA damage. 
Poly(ADP-ribose) polymerase (PARP) enzymes are a 
family of proteins shown to be involved in ssDNA 
repair. PARP inhibitors are a new class of drug that 
prevent PARP enzyme activity leading to persistence 
of spontaneous ssDNA breaks that progress to dsDNA 
breaks on replication [39]. BRCA mutated cells cannot 
repair these breaks leading to cell death, while nor-
mal cells are spared. This targeting of BRCA mutated 
cells by exploitation of their specific sensitivity to 
PARP inhibitors is called ‘synthetic lethality’ and has 
been the focus of a great deal of research in recent 
years. Olaparib is one of a number of PARP inhibi-
tors that have been investigated. A Phase III study 
of maintenance olaparib versus placebo has already 
been completed in women with recurrent HGSC [40]. 
Women receiving olaparib had an improvement in 
PFS which was much more pronounced in those who 
harboured a BRCA mutation (11.5 vs 5.6 months; 
p < 0.00001) [41]. This evidence, although involving 
retrospective BRCA evaluation, suggests that testing 
for BRCA status in women with HGSC has clinical 
significance. A Phase III trial called SOLO (Study of 
OLaparib in Ovarian cancer) has been designed to 
determine the benefit of olaparib as a maintenance 
monotherapy specifically in BRCA mutated ovar-
ian cancer patients. This strategy will be evaluated 
in both the first-line (SOLO1) [42] and second-line 
(SOLO2) [43] setting.
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Predicting relapse
Unfortunately the majority of patients with advanced 
ovarian cancer will go on to have relapse of their dis-
ease after frontline surgery and chemotherapy. There are 
many options for surveillance to detect relapse including 
serial measurement of the tumor marker cancer antigen 
125 (CA125), physical exam and a number of imaging 
modalities. Significant controversy exists about the rela-
tive effectiveness of each modality and their effect on 
survival and whilst detection of recurrences by physical 
exam alone is rare (4% of relapses), the combination of 
examination, history and elevated CA125 will detect up 
to 90% of recurrences [2].
CA125 is a glycoprotein which is elevated in up to 
88% of advanced ovarian cancers and has a role in both 
monitoring disease response and in follow-up. Rising 
CA125 may precede development of symptoms by a 
number of months and represents a significant manage-
ment dilemma; whether to treat when CA125 is first 
elevated or on the development of symptoms? This was 
addressed in a study by Rustin et al. [44] in which women 
who were in complete remission were randomized to 
early treatment of relapse on asymptomatic CA125 rise 
or treatment only on symptomatic recurrence. There 
was no significant difference between the two treatment 
arms (median survival: 25.7 vs 27.1 months) but women 
in the early treatment arm received more chemotherapy 
overall and had an earlier deterioration in quality of life. 
Therefore measuring CA125 alone is not sufficient to 
dictate timing of further treatment but must be used 
in conjunction with other investigations. Continuing 
developments in chemotherapy treatment and increas-
ing use of secondary debulking constantly change the 
options for disease treatment and mean that early detec-
tion may in the future allow improved outcomes
Although there are many imaging modalities avail-
able for ovarian cancer, there has been no OS benefit 
shown for serial radiological studies [2]. The most com-
monly used modality to guide treatment is computer 
tomography (CT). However, as an elevated CA125 
may precede CT findings by many months alternative 
imaging has been investigated to decide who requires 
immediate treatment. 18Fluorine deoxyglucose PET is 
a method of imaging based on the increased glucose 
metabolism of malignant tumors. It has been shown to 
detect ovarian relapses at an earlier stage during follow-
up with a sensitivity of up to 96% [45]. This suggests 
that fluorine deoxyglucose PET could play a role in early 
detection of relapses but it has yet to been proven to be 
useful in clinical trials.
Platinum-sensitive relapse
At relapse the period of time that has elapsed since last 
treatment with platinum-based compounds is prog-
nostic [3]. Patients who have relapsed more than 1 year 
after their last platinum-based treatment are classified 
as platinum sensitive and have approximately a 60% 
chance of response to further platinum containing 
chemotherapy. If relapse occurs following a platinum-
free interval (PFI) of 6–12 months patients are classi-
fied as partially platinum sensitive and have a reduced 
response rate of 25–40% to platinum agents. Patients 
who relapse with a PFI of less than 6 months are clas-
sified as platinum resistant and are not rechallenged 
with platinum-based regimes due to unacceptably low 
response rates.
In platinum sensitive relapse, second-line treatment 
will most commonly involve carboplatin. Research 
into combination therapy has shown that the addi-
tion of paclitaxel to a platinum regime gives superior 
survival at relapse [46]. However, this combination is 
accompanied by significant toxicity including periph-
eral neuropathy, neutropenia and alopecia. Carbopla-
tin plus gemcitabine is one alternative regime which 
has also shown superiority to carboplatin alone [47]. 
The CALYPSO [48] study compared the combination 
of pegylated liposomal doxorubicin (PLD) and carbo-
platin with standard carboplatin and paclitaxel at first 
relapse. The PLD arm had superior PFS (HR: 0.82; 
95% CI: 0.72–0.94; p = 0.005), although in subse-
quent analysis there was no difference in OS, poten-
tially due to unequal post study cross-over [49]. Overall 
more patients discontinued treatment in the standard 
arm due to severe nonhematologic toxicity, with the 
PLD arm having significantly less neuropathy and 
alopecia, but more nausea, mucositis and hand-foot 
syndrome. Therefore in the relapse setting carboplatin 
plus PLD is less toxic and likely more effective than 
carboplatin plus paclitaxel.
Angiogenesis inhibitors
Anti-angiogenic agents are known to have activity in 
the setting of platinum sensitive recurrence. The larg-
est randomized Phase III trial is the OCEANS trial [50] 
in which carboplatin and gemcitabine was trialled 
with and without the addition of concurrent bevaci-
zumab, which was continued until disease progression. 
PFS was superior in the bevacizumab arm (HR: 0.48; 
95% CI: 0.39–0.60; p < 0.0001) and has therefore been 
approved for use by the EMA and the cancer drugs 
fund (CDF) for first-line platinum-sensitive relapse in 
conjunction with carboplatin and gemcitabine only. 
There is currently no published data on the effective-
ness of bevacizumab for relapse after having received 
the drug in the first-line setting.
Cediranib is an oral tyrosine kinase inhibitor that 
also has inhibitory effects on VEGF/PDGF/FGF 
receptors and is similar in action to pazopanib [27]. 
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The ICON6 study enrolled patients following their 
first relapse with ovarian cancer. The control arm was 
standard chemotherapy, with two experimental arms 
of concurrent cediranib plus placebo maintenance 
or concurrent plus 18 months maintenance cedira-
nib. The trial showed the combination of cediranib 
and chemotherapy provided a 2.7 month advantage 
in OS (17.6 vs 20.3 months; HR: 0.7; p =0.04) and 
also extended PFS by 3.1 months (9.4 vs 12.5 months; 
HR: 0.68; p = 0.0022) thus showing a significant 
survival benefit to cediranib use [51].
The OCEANS trial which showed improvement in 
PFS but not OS and the ICON 6 trial which showed 
modest OS and PFS improvement strengthen the evi-
dence for a benefit from targeting the angiogenesis 
pathway in recurrent ovarian cancer, in addition to 
the evidence for targeting it in the frontline setting. 
On publication of the final results of ICON6 cedira-
nib will likely be an oral alternative to bevacizumab in 
recurrent ovarian cancer.
Partially platinum-sensitive relapse
The trials thus far described in this section primarily 
recruited patients with platinum-sensitive recurrence. 
For patients that relapse with a PFI of 6–12 months 
there is less consensus regarding rechallenge with plat-
inum-based regimes due to decreased response rates. 
In addition, platinum-based toxicities may be greater 
with a short PFI and therefore there is need for alter-
native nonplatinum agents. Trabectedin is a chemo-
therapy agent originally derived from the sea squirt 
Ecteinascidia turbinate, that has proven efficacy in 
relapsed ovarian cancer [52]. In the OVA-301 trial tra-
bectedin plus PLD was shown to have superior activity 
to PLD alone in relapsed ovarian cancer [53]. A total of 
214 patients in this study had partially platinum sensi-
tive disease and a subanalysis of these patients showed 
a median PFS of 7.4 months in the combination arm 
versus 5.5 months in the PLD arm (HR: 0.65; 95% 
CI: 0.45–0.92; p = 0.015) [54]. This was the largest dif-
ference for all PFI subsets analyzed therefore showing 
evidence for a specific benefit of trabectedin/PLD in 
partially platinum-sensitive disease. In addition, clini-
cal data suggest that the artificial expansion of PFI 
with an intervening nonplatinum therapy may be ben-
eficial [55], possibly by reversing platinum resistance. 
Within OVA-301 partially platinum sensitive patients 
in the trabectedin/PLD arm survived significantly 
longer after subsequent platinum treatment (HR: 
0.63; p = 0.0357; median: 13.3 vs 9.8 months) than 
those on PLD alone, thus supporting the hypothesis 
that artificially increasing PFI is important. The addi-
tional benefit for trabectedin/PLD therapy in terms 
of PFS and survival after further platinum therapy 
provides a new option for partially platinum-sensi-
tive patients. However, because platinum containing 
regimes remain a reasonable treatment option in this 
group and the evidence is based on subset analysis 
only, a trial is planned comparing carboplatin/PLD 
using the regimen evaluated in the CALYPSO trial 
with trabectedin/PLD [54].
Platinum-resistant relapse
Where the PFI is less than 6 months platinum agents 
have low response rates and the median survival is 
less than 12 months [56]. The mainstay of treatment 
is single agent therapies which have varying levels of 
activity. Weekly paclitaxel appears to have response 
rates of up to 25% [57]. Other commonly used thera-
pies such as topotecan and PLD have response rates 
of 10–15% [56]. Improvements on these poor response 
rates have been sought by adding anti-angiogenic fac-
tors. The AURELIA study investigated the addition 
of bevacizumab to single agent therapy from any of 
the previous mentioned single agents. Choice of ther-
apy was investigator directed depending on previous 
patient treatment tolerances. The addition of bevaci-
zumab showed a PFS advantage with a median PFS of 
6.7 months with chemotherapy plus bevacizumab ver-
sus 3.4 months with chemotherapy alone (HR: 0.48; 
95% CI: 0.38–0.60; p < 0.001) [58]. The improve-
ment in PFS is not dissimilar to the 1.5–3.8-month 
improvement in PFS seen in the adjuvant use of beva-
cizumab [28,29]. However, in the platinum-resistant set-
ting there is considerably less exposure to bevacizumab 
to gain the same improvement in PFS. This shows that 
anti-angiogenic treatment is active in all presentations 
of ovarian cancer resulting in an approximate 3 month 
improvement in PFS independent of PFI.
Novel chemotherapeutic agents
In the search for novel nonplatinum-based chemo-
therapeutic agents various lines have been investi-
gated. Over 80% of ovarian cancers overexpress the 
membrane bound folate receptor (FR), whereas it is 
poorly expressed or absent in most normal cells mak-
ing it an excellent candidate for targeted therapy. 
Farletuzumab, an FR targeted antibody, has shown 
disappointing results in Phase III trials [18]. How-
ever, vintafolide, a folate conjugated with the vinca 
alkaloid desacetylvinblastine monohydrazine, is spe-
cifically designed to target the FR delivering potent 
chemotherapy directly to cells overexpressing FR. 
PRECEDENT [59] is a Phase II study which assessed 
vintafolide with PLD versus PLD alone in recur-
rent ovarian cancer. This showed an improvement 
in PFS with a median survival of 5.0 months for the 
combination arm versus 2.7 months for the PLD 
www.futuremedicine.com 363future science group
The next steps in improving the outcomes of advanced ovarian cancer    Review
alone arm (HR: 0.63; 95% CI: 0.41–0.96; p = 0.031). 
This trial was run alongside evaluation of etarfolatide, 
which is a folate-technetium conjugate imaging agent 
that selectively binds FR-expressing cells analogous 
to the action of vintafolide. This allowed imaging 
of FR-expressing tumors via single photon emission 
computed tomography. Patients who had 100% of 
lesions positive for FR, had an improved PFS median 
of 5.5 months in the experimental arm compared with 
1.5 months for PLD alone. PROCEED, a random-
ized placebo controlled trial of vintafolide alongside 
etarfolatide imaging has been undertaken [60], but 
enrolment has been suspended due to a disappointing 
interim analysis. It is hoped that future developments 
of FR targeted drugs may be more successful.
Another area of interest has been in inhibition of 
the Phosphoinositide 3-kinase (PI3K)/AKT pathway. 
This has been shown to be overactive in ovarian can-
cer and may be involved in the resistance of ovarian 
cancer to platinum agents [61]. Inhibition of AKT is 
postulated to reverse chemotherapeutic resistance and 
therefore a Phase I/II study is underway to investi-
gate a novel AKT inhibitor GSK2110183 when given 
alongside carboplatin and paclitaxel [62].
Immunotherapy
There is evidence that the human immune system 
generates tumor reactive immune cells that have 
anti-tumor potential. Therefore modulation of this 
response represents a rational therapeutic approach 
to the treatment of ovarian cancer [18]. The most well 
developed area of research in ovarian cancer immu-
notherapy is dendritic cell (DC)-based vaccines. 
DCs capture, process and present antigens including 
tumor-associated antigens thereby inducing the gen-
eration of effector and memory T cells [63]. The activ-
ity of these cells is believed to be responsible for the 
observed antitumor effects. The design of DC therapy 
in ovarian cancer is in the early stages but there have 
been encouraging findings in the treatment of pros-
tate cancer [64]. DC vaccines are usually prepared ex 
vivo. Autologous immune cells collected from patients 
are treated with a range of peptides, mRNA, proteins, 
tumor lysates or other agents before reintroduction 
to the patient [63]. The best immunizing antigens are 
currently unknown but the use of a cell surface associ-
ated mucin 1 dendritic vaccination is the most exten-
sively studied and CA125 responses have been seen in 
response to their use [65]. A Phase II trial (CAN-003) 
randomizing 56 patients in remission after first or sec-
ond-line therapy to DC vaccine or standard observa-
tional care has demonstrated safe use of a mucin 1 DC 
vaccine and a significant increase in PFS in patients 
after second-line therapy (median PFS for observation 
4.94 months vs ‘not reached’ but greater than 12.91 
months for DC vaccine [p = 0.04]) [66]. A larger ran-
domized Phase II trial called CANVAS has been initi-
ated to further investigate this vaccine’s effectiveness 
in first- and second-line remission [67].
Programed cell death 1 (PD-1) is an inhibitory 
surface receptor expressed by a number of immune 
cells including B and T cells that binds to the pro-
gramed cell death ligand 1 (PD-L1). The expression 
of PD-L1 in tumors is inversely correlated with sur-
vival of patients, as tumor cells are believed to activate 
the PD-1 inhibitory pathway to evade the immune 
response. In animal models antibody mediated PD-1 
blockade enhanced tumor immunity [68], suggesting 
that targeted interventions against this pathway may 
increase antitumor immunity in ovarian cancer and 
may compliment developments in DC vaccination.
Future perspective
As we begin to understand how different ovarian can-
cers respond to standard chemotherapy, novel agents 
and targeted agents, the tailoring of treatment to a 
cancer’s histological and genetic makeup will become 
increasingly important. Whole-exome DNA sequenc-
ing of 316 ovarian cancer samples has shown that 
TP53 mutations occur in virtually all (96%) patients 
and that a number of genes are mutated in a subset 
of high-grade serous ovarian cancers. BRCA1 and 
BRCA2 had germline mutations in 9 and 8% of cases, 
respectively, and there were somatic mutations in a 
further 3% of cases. Six other genes were also shown 
to be statistically recurrently mutated: RB1, NF1, 
FAT3, CSMD3, GABRA6 and CDK12 [69]. Although 
the clinical significance of these mutations has yet to 
be fully elucidated, it lends credence to the theory that 
there may be other genetic mutations besides BRCA 
that could be targeted to improve outcomes. Spatial 
heterogeneity of cancer mutations within the same 
person suggests that single biopsies should not be used 
as the sole specimen when deciding on personalized 
medicine [70].
The TP53 tumor suppressor gene is a key regulator 
of cell cycle arrest or cell death upon oncogenic stress. 
Most TP53 mutations are missense mutations that 
result in dysfunctional p53 protein allowing cell survival 
and division. Restoration of wild type p53 function can 
therefore induce cell death and tumor regression. APR-
246 is a compound that can restore wild type confor-
mation to mutant p53. It has been tested in a Phase I/II 
clinical trial involving 22 patients with hematological 
malignancies or hormone-refractory prostate cancer. 
Drug safety has been confirmed and clinical effects 
have been observed [71]. Due to the frequency of TP53 
mutations in ovarian cancer, restoring p53 activity with 
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APR-246 is an area of current research. PiSARRO, a 
Phase Ib/II study assessing carboplatin combination 
chemotherapy with or without APR-246 in relapsed 
platinum-sensitive disease has been designed [72] spe-
cifically to investigate the effectiveness of modifying 
dysfunctional p53 to attain disease control.
A potential barrier to targeted therapy is that the 
mutations may change over time, such as when the tumor 
becomes resistant to chemotherapy treatment. There-
fore, a method of detecting these changes is important 
and in early development are techniques such as cir-
culating tumor DNA analysis [73]. The ALFApump® 
system provides an alternative way to obtain whole cell 
DNA. It has been developed to continuously drain asci-
tes into the bladder [74] and is currently being trialed in 
advanced ovarian cancer. An exciting possibility is to 
continuously monitor the genetic mutations of cancer 
cells present within urine due to the presence of the 
pump. As the urine may include cells from multiple 
tumor sites within the peritoneal cavity it may provide 
Executive summary
Advances in surgery
•	 Primary cytoreductive surgery to no macroscopic disease shows the greatest improvements in 5-year survival.
•	 The benefit of optimal surgical debulking within the peritoneal cavity is present even in patients with stage IV 
disease.
•	 Neoadjuvant chemotherapy reduces morbidity due to surgery but there are concerns that surgery at a delayed 
time point may compromise effective surgical disease clearance.
•	 Debulking surgery at relapse may be indicated if complete macroscopic tumor clearance can be achieved. 
Ongoing trial DESKTOP III.
Adjuvant chemotherapy
•	 Carboplatin and paclitaxel three weekly is the standard of care. The intraperitoneal route may be considered 
in selected patients.
•	 Dose dense paclitaxel given with carboplatin may have a survival advantage. Ongoing research is with ICON8.
•	 Bevacizumab and pazopanib in addition to standard chemotherapy improve progression-free survival.
•	 Intraperitoneal chemotherapy has superior efficacy at the potential cost of increased adverse effects.
Breast cancer (BRCA)-related disease
•	 BRCA-related disease is more sensitive to platinum-based chemotherapy.
•	 Intraperitoneal platinum chemotherapy may be more effective in BRCA mutation carriers.
•	 PARP inhibitors show an improvement in progression-free survival on initial trials. Further research will be 
undertaken in the SOLO 1 & SOLO 2 trials.
Predicting relapse
•	 The majority of patients with advanced ovarian cancer will go on to have relapse of their disease.
•	 There is evidence that CA125 monitoring is not necessary during follow-up.
•	 An asymptomatic CA125 rise with no lesion on imaging represents a prognostic dilemma and current 
information indicates they do not need treatment until symptomatic.
Platinum & partially platinum-sensitive relapse
•	 Rechallenge with a platinum-containing regime is mandatory if tolerated.
•	 The combination of pegylated liposomal doxorubicin and carboplatin is less toxic and likely more effective 
than carboplatin paclitaxel.
•	 Use of bevacizumab or cediranib show a progression-free survival advantage when given with standard 
chemotherapy.
•	 Trabectedin is a novel chemotherapy agent with appears most effective in partially platinum-sensitive disease.
Platinum-resistant relapse
•	 Where the platinum-free interval is less than 6 months platinum agents have low response rates.
•	 Chemo-monotherapy is the mainstay of treatment.
•	 The addition of bevacizumab to chemo-monotherapy in the AURELIA study showed a progression-free survival 
advantage similar to that seen in the adjuvant setting.
•	 Folate-receptor targeted chemotherapy agents are an area of current interest.
•	 Immunotherapy using dendritic cell vaccines is a promising area of future research.
Future perspective
•	 The use of targeted therapies based on the detected mutations of the tumors will be of increasing importance 
in tailoring anticancer therapy.
•	 TP53 is almost ubiquitously mutated in ovarian cancer and drugs that can modify dysfunctional p53 are an 
important area of research. Ongoing trial PiSARRO.
•	 Spatial and temporal variation in tumor characteristics and mutations is a significant barrier to effective 
personalized medicine.
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a method to monitor both spatial and temporal genetic 
change allowing a more comprehensive assessment for 
personalized medical care.
In summary the treatment of ovarian cancer draws 
on a wide knowledge of expertise. Advances in its 
treatment are diverse and include new surgical treat-
ments, use of an increasing number of imagining 
modalities, new uses of existing therapies and the 
development of novel chemotherapeutic agents and 
targeted therapies. It is likely that each of these will 
have an impact on the disease such that there will 
be a continued improvement in 5-year survival and 
a gradual increase in the percentage of patients who 
achieve a long-term cure. The future is promising, 
and with each step forward the lives of patients will be 
inexorably improved.
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